Search for a trial

1 results

A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR;
targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated with Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

Approved WMORecruitment stopped

The aim of this phase IVI, randomized, open-label study is to compare the efficacy of cabazitaxel versus an AR targeted agent, in patients previously treated with docetaxel and likely to have primary resistance to AR targeted agents.

A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR; targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated with Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR;
targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated with Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)